Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

AstraZeneca (AZN) Share Price & Analysis

1,060 Followers

AZN Stock Chart & Stats

GBX 14,024.00GBX 264.00(1.92%)
At close: 4:30 PM GMT
12K p13K p14K pAug 10Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2
Day’s Range
GBX 13,582.00 - GBX 14,062.00
52-Week Range
GBX 10,524.00 - GBX 15,732.00
Previous Close
GBX 13,760.00
Volume
N/A
Average Volume (3M)
2.55M
Market Cap
GBP 213.41B
Enterprise Value
GBP 211.22B
Total Cash (Recent Filing)
GBP 8.11B
Total Debt (Recent Filing)
GBP 33.97B
Price to Earnings (P/E)
26.6
Beta
1.19
Next Earnings
Feb 11, 2027 (Est.)
EPS Estimate
1.72
Last Dividend Ex-Date
Aug 06, 2026
Dividend Yield
1.70%

Bulls Say, Bears Say

Bulls Say

Broad Portfolio Growth

Growth across several major therapy areas and regions reduces reliance on any single medicine or market. This breadth supports more resilient revenue compounding, strengthens commercial scale, and provides a durable platform for absorbing weakness in mature products.

Deep Pipeline And Innovation

A large late-stage pipeline gives AstraZeneca multiple opportunities to replenish and expand its medicine portfolio as existing products mature. Repeated clinical and regulatory catalysts can extend growth, diversify future revenue, and reinforce its competitive position.

Strong Profitability And Balance Sheet

Improving margins and a growing equity base indicate substantial earnings power and financial resilience. Strong profitability can fund research, business development, and shareholder returns while helping the company support its broad innovation program over time.

Bears Say

Loss-of-exclusivity Pressure

Patent and biosimilar erosion is reducing revenue from important established medicines, creating a recurring replacement requirement for the pipeline. Continued generic competition can pressure growth and margins until newer launches become large enough to offset declines.

Mixed Cash Conversion

A meaningful gap between earnings and cash generation can constrain internally funded investment and shareholder returns if it persists. Lower operating cash flow despite higher earnings also increases reliance on working-capital normalization and disciplined cash management.

Restructuring And Investment Burden

Higher capital spending, deal-related payments, and restructuring costs will absorb cash while AstraZeneca continues investing heavily in research. Although intended benefits are substantial, execution over several years may pressure near-term margins and financial flexibility.

AstraZeneca News

AZN FAQ

What was AstraZeneca’s price range in the past 12 months?
AstraZeneca lowest share price was 10524.00 p and its highest was 15732.00 p in the past 12 months.
What is AstraZeneca’s market cap?
AstraZeneca’s market cap is £213.41B.
When is AstraZeneca’s upcoming earnings report date?
AstraZeneca’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 97 days.
How were AstraZeneca’s earnings last quarter?
AstraZeneca released its earnings results on Oct 30, 2026. The company reported 2.068 p earnings per share for the quarter, beating the consensus estimate of 1.917 p by 0.151 p.
Is AstraZeneca overvalued?
According to Wall Street analysts AstraZeneca’s price is currently Undervalued.
Does AstraZeneca pay dividends?
AstraZeneca pays a Semiannually dividend of 79.5 p which represents an annual dividend yield of 1.7%. See more information on AstraZeneca dividends here
What is AstraZeneca’s EPS estimate?
AstraZeneca’s EPS estimate is 1.72.
How many shares outstanding does AstraZeneca have?
AstraZeneca has 1,551,065,200 shares outstanding.
What happened to AstraZeneca’s price movement after its last earnings report?
AstraZeneca reported an EPS of 2.068 p in its last earnings report, beating expectations of 1.917 p. Following the earnings report the stock price went up 6.957%.
Which hedge fund is a major shareholder of AstraZeneca?
Hedge funds hold AstraZeneca shares: the largest hedge-fund position in AstraZeneca is 70,146,550 shares, and hedge funds increased their holdings by 2.6M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology